Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACIU NASDAQ:FBRX NASDAQ:IMA NASDAQ:INDP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACIUAC Immune$2.40+0.4%$2.89$1.65▼$4.00$244.25M1.59306,704 shs218,403 shsFBRXForte Biosciences$16.69-1.8%$25.84$9.10▼$35.80$231.82M2.87261,505 shs272,959 shsIMAImageneBio$5.69+4.4%$5.53$3.94▼$18.00$60.60M0.72222,110 shs5,534 shsINDPIndaptus Therapeutics$4.75+114.9%$2.07$0.92▼$19.91$537.89M1.25360,833 shs39.78 million shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACIUAC Immune-1.03%-18.26%-19.63%-12.27%+45.15%FBRXForte Biosciences-6.44%-20.82%-39.69%-43.86%+78.01%IMAImageneBio0.00%-8.09%-3.71%-9.77%-66.36%INDPIndaptus Therapeutics+2.79%+74.02%+3.27%+16.32%-77.30%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACIUAC Immune$2.40+0.4%$2.89$1.65▼$4.00$244.25M1.59306,704 shs218,403 shsFBRXForte Biosciences$16.69-1.8%$25.84$9.10▼$35.80$231.82M2.87261,505 shs272,959 shsIMAImageneBio$5.69+4.4%$5.53$3.94▼$18.00$60.60M0.72222,110 shs5,534 shsINDPIndaptus Therapeutics$4.75+114.9%$2.07$0.92▼$19.91$537.89M1.25360,833 shs39.78 million shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACIUAC Immune-1.03%-18.26%-19.63%-12.27%+45.15%FBRXForte Biosciences-6.44%-20.82%-39.69%-43.86%+78.01%IMAImageneBio0.00%-8.09%-3.71%-9.77%-66.36%INDPIndaptus Therapeutics+2.79%+74.02%+3.27%+16.32%-77.30%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACIUAC Immune 2.25Hold$7.50212.50% UpsideFBRXForte Biosciences 2.50Moderate Buy$67.00301.44% UpsideIMAImageneBio 2.00Hold$26.50365.73% UpsideINDPIndaptus Therapeutics 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest IMA, ACIU, FBRX, and INDP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/11/2026IMAImageneBio WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingUnderperform5/8/2026ACIUAC Immune Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/4/2026ACIUAC Immune BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.004/21/2026INDPIndaptus Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026ACIUAC Immune Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/27/2026FBRXForte Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/16/2026ACIUAC Immune BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.003/13/2026ACIUAC Immune Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$7.00(Data available from 6/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACIUAC Immune$4.31M56.67N/AN/A$0.54 per share4.44FBRXForte BiosciencesN/AN/AN/AN/A$4.71 per shareN/AIMAImageneBio$800K75.75N/AN/A$11.91 per share0.48INDPIndaptus TherapeuticsN/AN/AN/AN/A$1.40 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACIUAC Immune-$85.03M-$0.82N/A14.12N/A-1,788.02%-125.26%-40.85%8/4/2026 (Estimated)FBRXForte Biosciences-$69.38M-$4.64N/AN/AN/AN/A-106.17%-85.50%8/13/2026 (Estimated)IMAImageneBio-$45.35M-$5.79N/AN/AN/AN/A-38.96%-34.60%N/AINDPIndaptus Therapeutics-$20.85M-$15.40N/AN/AN/AN/A-1,030.07%-299.69%8/17/2026 (Estimated)Latest IMA, ACIU, FBRX, and INDP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026INDPIndaptus Therapeutics-$1.87-$0.23+$1.64-$0.23N/AN/A5/11/2026Q1 2026FBRXForte Biosciences-$1.16-$1.24-$0.08-$1.24N/AN/A5/7/2026Q1 2026IMAImageneBio-$0.70-$0.95-$0.25-$0.95N/AN/A4/30/2026Q1 2026ACIUAC Immune-$0.20-$0.19+$0.01-$0.19$0.33 million$1.40 million3/31/2026Q4 2025FBRXForte Biosciences-$1.42-$1.45-$0.03-$1.45N/AN/A3/17/2026Q4 2025INDPIndaptus Therapeutics-$4.36-$3.10+$1.26-$3.10N/AN/A3/13/2026Q4 2025ACIUAC Immune-$0.19-$0.18+$0.01-$0.18$1.14 million$0.44 million3/10/2026Q4 2025IMAImageneBioN/A$0.34N/A$0.34N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthACIUAC ImmuneN/AN/AN/AN/AN/AFBRXForte BiosciencesN/AN/AN/AN/AN/AIMAImageneBioN/AN/AN/AN/AN/AINDPIndaptus TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACIUAC Immune0.110.871.02FBRXForte BiosciencesN/A2.752.75IMAImageneBioN/A18.3918.39INDPIndaptus TherapeuticsN/A2.342.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACIUAC Immune51.36%FBRXForte Biosciences77.63%IMAImageneBio75.00%INDPIndaptus Therapeutics7.06%Insider OwnershipCompanyInsider OwnershipACIUAC Immune4.60%FBRXForte Biosciences4.40%IMAImageneBio5.94%INDPIndaptus Therapeutics23.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACIUAC Immune140101.77 million97.09 millionOptionableFBRXForte Biosciences513.89 million13.28 millionOptionableIMAImageneBio7010.65 million10.02 millionNot OptionableINDPIndaptus Therapeutics6113.24 million86.52 millionNot OptionableIMA, ACIU, FBRX, and INDP HeadlinesRecent News About These CompaniesHead to Head Analysis: Indaptus Therapeutics (NASDAQ:INDP) and Wellgistics Health (NASDAQ:WGRX)June 3 at 7:05 AM | americanbankingnews.comIndaptus Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 15, 2026 | globenewswire.comIndaptus Therapeutics Adds Independent Directors Amid Board RefreshApril 23, 2026 | tipranks.comIndaptus Therapeutics Appoints David Natan to BoardJanuary 8, 2026 | tipranks.comBiolojic Design appoints new chief medical officerJanuary 8, 2026 | thepharmaletter.comTIndaptus Therapeutics announces upcoming board leadership transitionJanuary 3, 2026 | msn.comIndaptus Therapeutics enters $6M securities purchase agreement with David LazarDecember 29, 2025 | msn.comIndaptus Therapeutics stock falls after $6 million securities dealDecember 29, 2025 | za.investing.comWhy did INDP stock gain 12% today?December 29, 2025 | msn.comIndaptus Therapeutics Secures $6 Million Investment from David E. Lazar, Appoints Him Co-CEO and ChairmanDecember 29, 2025 | quiverquant.comQIndaptus Enters Into $6 Million Securities Purchase Agreement with Investor David E. LazarDecember 29, 2025 | globenewswire.comIndaptus Therapeutics (INDP) Price Target Decreased by 60.00% to 10.20November 17, 2025 | msn.comIndaptus Therapeutics to Present Advances in Allogeneic Immune Cell Therapy at 3rd Donor Selection & Cell Source SummitNovember 17, 2025 | quiverquant.comQIndaptus Therapeutics Chief Scientific Officer Dr. Michael Newman to Present at the Donor Selection & Cell Source SummitNovember 17, 2025 | globenewswire.comIndaptus Therapeutics Reports Q3 2025 Financial Results and Corporate UpdateNovember 12, 2025 | quiverquant.comQIndaptus Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateNovember 12, 2025 | globenewswire.comIndaptus Therapeutics (INDP) Price Target Decreased by 86.15% to 25.50October 29, 2025 | msn.comIndaptus Therapeutics stock falls after mixed clinical trial updatesSeptember 6, 2025 | za.investing.comIndaptus Therapeutics provides update on INDP-D101 clinical trialSeptember 5, 2025 | msn.comIndaptus Therapeutics Reports Positive Monotherapy Results for Decoy20 in Urothelial Cancer, Initiates Combination Therapy with TislelizumabSeptember 4, 2025 | quiverquant.comQNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX IPO: Opportunity? Or the Ultimate Hype Trade?By Chris Markoch | May 22, 2026Rocket Lab Posts Record Q1 Revenue, Raises Q2 GuidanceBy Ryan Hasson | May 8, 20263 Industrial Stocks That Just Crushed EarningsBy Dan Schmidt | May 13, 2026Boarding Passes Now Being Issued for the Ultimate eVTOL ArbitrageBy Jeffrey Neal Johnson | May 6, 2026AI’s Biggest Bottleneck Could Make These 2 Stocks SoarBy Jeffrey Neal Johnson | May 28, 2026IMA, ACIU, FBRX, and INDP Company DescriptionsAC Immune NASDAQ:ACIU$2.40 +0.01 (+0.42%) Closing price 04:00 PM EasternExtended Trading$2.40 +0.00 (+0.21%) As of 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.Forte Biosciences NASDAQ:FBRX$16.69 -0.31 (-1.82%) Closing price 04:00 PM EasternExtended Trading$16.66 -0.04 (-0.21%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.ImageneBio NASDAQ:IMA$5.69 +0.24 (+4.40%) Closing price 04:00 PM EasternExtended Trading$5.70 +0.01 (+0.18%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ImageneBio, Inc., a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.Indaptus Therapeutics NASDAQ:INDP$4.75 +2.54 (+114.93%) Closing price 04:00 PM EasternExtended Trading$3.77 -0.98 (-20.59%) As of 04:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Generac’s AI Power Pivot Raises a Bigger Question About Data Center Demand Medtronic Bottoms, Healthy Rebound Ahead From Runway to Riches: Victoria's Secret's New Look Coke's $10B India IPO Plan Pops the Top on Hidden Value Dell's AI Toll Bridge Is Paved with Record Margins The Blue Origin Explosion Is a Setback for Amazon, Not a Dealbreaker GitLab’s Price Recovery Gains Traction—Time to Get On Board? Ulta's Q1 Report Primes It for a Beauty of a Rebound Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
